The European Commission has granted authorization for an enhanced COVID-19 vaccine developed by Pfizer in collaboration with its German partner BioNTech to be included in the upcoming autumn vaccination campaigns across EU countries. This updated vaccine is specifically designed to target the prevalent Omicron XBB.1.5 variant, according to an announcement made on Friday.
The vaccine, known as Comirnaty, represents the third adapted vaccine to be employed within the European Union. The Commission’s authorization covers the use of Comirnaty for individuals, including adults, children, and infants above six months of age.
Earlier this week, the European Medicines Agency (EMA) granted its approval for this vaccine. Both the EMA and the European Centre for Disease Prevention and Control have recommended a single dose of this vaccine, regardless of an individual’s prior vaccination history.
The European Union revised its agreement with Pfizer in May, which led to a reduction in the number of vaccine doses ordered due to decreased demand. This updated contract extends the vaccine supply deadline until 2026 and ensures access to modified vaccines designed to combat emerging variants.
